Introduction
B-lineage cells, in particular antibody-secreting plasma cells (PCs), are the unique source of protective and autoreactive antibodies. In systemic lupus erythematosus (SLE), B cells and autoantibodies, including immune complexes, are considered to be intimately involved in the very complex pathogenesis of SLE as well as a number of other autoimmune diseases [1] [2] [3] [4] . Th e appealing concept to ameliorate disease by abrogating autoantibody production and thereby reducing autoantibody-dependent eff ector mechanisms has served as the main rationale for the use of B-cell-directed therapies in patients with SLE in addition to the inhibition of B-cell-mediated processes such as antigen presentation, cytokine production and activation of T cells. Ultimately, however, diff erentiated PCs largely resist these therapeutic approaches -and by continuing to produce autoantibodies, they appear to play an important immunopathogenic role by providing long-lived immune memory, as has been suggested by murine lupus models and data from SLE patients undergoing successful autologous stem cell transplan tation (ASCT) [5] . Th ese patients show clinical improvement together with the disappearance of autoreactive antibodies as well as normalization of T-cell and B-cell abnormalities in peripheral blood [5] . Independent of the very intense protocols of ASCT unspecifi cally targeting PCs, more selective therapeutic interventions are under consideration (recently reviewed in detail [6] ) -such as the use of monoclonal antibodies directed against B-cell surface antigens, like CD19, that may directly target PCs beyond other anti-B-cell approaches such as anti-CD20, anti-CD22 and anti-CD52 therapies ( Table 1 ).
In addition, other principles indirectly targeting these cells by depriving signals required for PC growth and diff erentiation are also being studied ( Table 2 ). B-cell activating factor (BAFF), TNFα, IL-6, IL-21, granulocytemacrophage colony-stimulating factor, IFNα as well as other cytokines and signals aff ect to diff erent degrees the survival, diff erentiation and function of B cells [7] or PCs [8, 9] . While in vivo data from such interventions are very limited, the extent of cytokine-blocking eff ects on PCs remains largely unknown.
Th e members of the TNF family BAFF (B-cell activating factor, or BlyS, B-lymphocyte stimulator, TNFSF13B) and APRIL (a proliferation-inducing ligand, TNFSF13A), which share receptors on B cells and PCs -that is, BAFF receptor (TNFRSF13C), BCMA (B-cell maturation antigen, TNFRSF17) and TACI (transmembrane activator Abstract Anti-CD20 therapy using rituximab directly targeting B cells has been approved for treatment of non-Hodgkin lymphoma, rheumatoid arthritis and anti-neutrophil cytoplasmic antibody-associated vasculitides and has led to reappreciation of B-lineage cells for antirheumatic treatment strategies. Moreover, blocking B-cell activating factor with belimumab, a drug that is licensed for treatment of active, seropositive systemic lupus erythematosus (SLE), represents an alternative, indirect anti-B-cell approach interfering with proper B-cell development. While these approaches apparently have no substantial impact on antibodysecreting plasma cells, challenges to improve the treatment of diffi cult-to-treat patients with SLE remain. In this context, anti-CD19 antibodies have the promise to directly target autoantibody-secreting plasmablasts and plasma cells as well as early B-cell diff erentiation stages not covered by anti-CD20 therapy. Currently known distinct expression profi les of CD19 by human plasma cell subsets, experiences with anti-CD19 therapies in malignant conditions as well as the rationale of targeting autoreactive plasma cells in patients with SLE are discussed in this review. and calcium modulator and cyclophilin ligand interactor, TNFRFS13B) -are also currently studied as therapeutic targets [10] . In vivo blockade of BAFF/APRIL strongly diminishes the mature PC compartment in mice [11] , and inhibition of both BAFF and APRIL by TACI-Ig (Atacicept) has been studied in early trials with patients with SLE [12] and rheumatoid arthritis (RA) [13] , providing evidence for reductions of autoreactive but also of total serum immunoglobulin (Ig) levels under treatment. Total Ig reductions of comparable magnitude have also been observed under anti-BAFF therapy with belimumab without aff ecting APRIL [14] , leaving it open whether BAFF has a role in supporting survival of human PCs in vivo (via TACI signaling) or whether certain Ig produced by PCs can also be reduced by indirect targeting of their precursors (via BAFF receptor). Th e latter is supported by data demonstrating a moderate reduction of plasmablast numbers by ~50% in the blood of belimumabtreated SLE patients [15] . However, the impact of belimumab on systemic antibody production occurred within a limited magnitude and with variable eff ects on diff erent Ig subclasses and on autoreactive versus total Ig levels [12] [13] [14] [15] . Th e clinical value of belimumab in SLE [14] could also involve targeting of B-cell functions other than autoantibody production. In this regard, B-cell development at the stage of transitional B cells is aff ected by this treatment [16] .
Based on the serum Ig data serving as a surrogate parameter for its eff ect on PCs, it is diffi cult to diff erentiate between the putative impact of anti-BAFF and TACI-Ig on mature PCs versus plasmablasts recently generated from activated B cells. Although no direct comparison exists, both strategies show partial eff ects on IgM, IgG and IgA production. Th ese data, however, do not allow a distinction between actual reduced PC numbers or simply a reduced capacity to produce Ig.
Overall, the clinical value of direct depletion of autoantibody-producing PCs in the bone marrow (BM) has not yet been suffi ciently addressed in autoimmunity. Currently available immune therapies leave these cells largely intact. Under rituximab treatment, tissue-resident and to some degree circulating ´steady-state´ PC pools [17] [18] [19] as well as specifi c (protective) serum Ig levels [20, 21] remain largely stable. Another anti-CD20 therapy employing ocrelizumab led to some reductions in serum IgM, IgG and IgA levels, but the dynamics appeared within the normal range of Ig subclass titers [22] . Notably, the discordance between autoantibody reduction and clinical effi cacy seen in SLE patients under rituximab treatment raised questions about the mechanism of action of anti-CD20 therapy and the value of more substantial PC depletion beyond anti-CD20 reach [23] .
Although the presence or levels of autoantibodies represent a surrogate for successful interventions, none of the above immune interventions but ASCT [5] have been shown to completely eradicate autoantibodies along with clinical remission status. An appealing hypothesis is therefore that successful targeting of autoreactive PCs via partial or complete depletion of the PC repertoire might constitute a therapeutic option for SLE and other autoimmune diseases, and could provide ultimate proof for the concept of autoantibody-driven immunopathology. 
Plasma cells and their microenvironment
PCs are destined to produce and secrete large amounts of specifi c antibodies, and by this means to importantly contribute to immune protection but also to autoimmunity through generation of autoreactive antibodies. In general, PCs diff erentiate from activated B cells -a process infl uenced by various factors that determine the timing and site of PC diff erentiation and maturation (that is, primary vs. secondary responses, splenic vs. lymph node vs. ectopic diff erentiation), the localization and physiological role of the PCs (that is, mucosal vs. systemic lymphoid tissues), conferring antibody availability at mucosal surfaces versus blood serum [24, 25] , and the quality of antibody produced by PCs (for example, T-cellindependent vs. T-cell-dependent responses, nature of antigen; recently reviewed in [7] ). Mature PCs represent the terminal stage of B-cell diff erentiation and are molecularly characterized by radical remodeling of their transcriptional program from a paired box 5 (PAX5)/Bcell-specifi c activator protein (BSAP)-dictated state to a Blimp-1 regulated state [26, 27] . PCs reside in the spleen, BM and the mucosal lamina propria, but are also found in lymph nodes and at sites of autoimmune infl ammation and in circulation [3, 7] . PCs of the BM in particular are considered to be the major source of serum Ig [28, 29] and at the same time have been suggested to contain a fraction of long-lived cells [30, 31] , which might account for the observed stability of specifi c serum antibody titers over decades [7, 32, 33] . Such stability of Ig-producing PCs has also been demonstrated in a lupus mouse model, including autoreactive PCs producing an anti-dsDNA idiotype, D42 [34] . In many SLE patients, anti-dsDNA IgG antibodies are reduced upon B-cell-depleting therapy with rituximab. At the same time, protective IgG but also anti-Ro and anti-La antibodies remain stable and hardly change after B-cell depletion [21, 35] . Th ese observations suggest that some autoantibody specifi cities are produced by longlived PCs being refractory to rituximab treatment, while other specifi cities partly depend on the presence of CD20 + B cells and presumably the generation of new plasmablasts or short-lived PCs [36] .
As mature PCs appear as resting cells [37, 38] , the survival of individual PCs is critical for the maintenance of serum Ig. PCs die rapidly when isolated ex vivo due to specifi c pathways of apoptosis [39] , unless they receive molecular signals that confer their survival. Th is property contributed to the concept of a molecular niche that conditionally maintains PCs in the BM and at the same time limits their numbers in healthy individuals [36, 40] . Soluble and insoluble signals such IL-5, IL-6, CXCL12, TNFα, APRIL and CD44 ligation have been demonstrated to facilitate PC survival in vitro [7, 8] , and various cell types able to produce these factors have been identifi ed in close proximity to PCs in the BM or spleen [9, 41] . Th ese cell types include stromal cells [42, 43] , eosinophils [44] or myeloid precursor cells [45] , megakaryocytes [46] and dendritic cells [41, 47] . Further cell types are directly (or suggested to be) implicated in PC survival; for example, basophils [48] , monocytes [49] , osteoclasts [15] and osteoblasts [50] . In addition, Xiang and colleagues suggested that the inhibitory Fc receptor FcγRIIb expressed by PCs may regulate their survival via apoptosis control [51] . Notably, PCs from lupus mice lacked expression of FcγRIIb and were protected from apoptosis. Th e implications of these fi ndings for human SLE remain unknown. Th e regulation of PC survival probably employs both redundancy and synergy as regulatory principles, as suggested by the multitude of factors and cells implicated in PC survival; for example, IL-6 and CXCL12 could partly compensate for the absence of BAFF and APRIL, or vice versa. Improved understanding of the microarchitecture hosting PCs contributes to potential anti-PC approaches by depriving them of their survival factors.
In this context, PCs also reside in kidneys of SLE patients or lupus-prone NZB/W mice [52, 53] . Although it is not known whether these cells have distinct requirements for their survival compared with BM PCs, their disappearance after resolution of infl ammation indicates that PC survival is extrinsically regulated, including micro environmental requirements. Studies on cells and soluble factors present in ectopic sites comprising PCs may thus help to defi ne the essential constituents of the PC niche. Conventional therapies including glucocorticoids and cytostatic drugs such as cyclophosphamide or mycopheno late motefi l have very limited impact on mature resting PCs, including autoreactive PCs [34, 37, 54, 55] . Proteasome inhibition with bortezomib aff ecting B cells and PCs among various other cell types leads to improvement of murine SLE including suppression of anti-dsDNA production [56] , whereas data from patients are still very limited [57] . Moreover, immunoablation by rabbit anti-thymocyte globulin (rATG) combined with ASCT [5] represents a unique strategy to abrogate autoantibody production (including protective antibodies) and shows promise for clinical effi cacy in severe SLE. Th e combined clinical and laboratory data from these patients exemplify the critical pathogenic role of the adaptive immune system in SLE, and provide the proof of concept that immune tolerance can be re-established in these patients.
In this regard, CD19 appears to be a candidate target molecule for specifi c targeting of B cells and PCs, since it has promise to add to the mechanisms of rituximab (that is, through the depletion of CD20 + B cells) the depletion of CD19 + CD20cells -that is, PCs and at least some pro/ pre-B cells (CD19 + CD20 -CD38 + CD10 + CD24 + IgD -), both of which are only limitedly reduced by rituximab treatment [17, 18] . In contrast to CD20 with hitherto largely unknown function, CD19 is known to be contained in the B-cell receptor (BCR) complex, regulating its activation threshold [58] . In line with this, defects in CD19 expression or function elicit autoantibody production in mice and also may contribute to human autoimmunity. Dysregulated CD19 expression has been reported in patients with systemic sclerosis, SLE and antineutrophil cytoplasmic antibody (ANCA)-associated vascu litis. To evaluate CD19 as a candidate target of therapy, we will discuss aspects of its expression on B cells and PCs with particular emphasis on SLE.
Expression and function of CD19

Expression of CD19 and its regulation
CD19 is a 95 kDa transmembrane glycoprotein of the immunoglobulin superfamily encoded by the CD19 gene that is expressed under the control of the transcription factor BSAP (encoded by PAX5) [59] [60] [61] , a master regulator of B-cell identity [62, 63] . No other transcriptional regulator has been identifi ed to bind to the CD19 promoter [59] , so CD19 expression probably recapitulates the activity of PAX5/BSAP. Consistently, CD19 is expressed by B lymphocytes but not by any other cell type, except for an unconfi rmed report suggesting CD19 expression by some follicular dendritic cells [64] .
In B cells, expression of CD19 (also referred to as B4 antigen) starts prior to the expression of CD20 (B1 antigen) at the late pro-B-cell stage together with that of CD10 [65] [66] [67] . CD19 expression is maintained throughout various B-cell diff erentiation and activation stages until PC diff erentiation, which is then associated with partial loss of CD19 expression ( Figure 1 ).
Regular expression of CD19 appears to require CD81, as CD81-defi cient mice show a 50% decrease in CD19 expression as compared with controls [68] and a patient defi cient in CD81 did not express CD19 on the B-cell surface despite the expression of intact CD19 alleles [69] . BCR defi ciency and mutations in Btk are associated with higher and lower CD19 expression by circulating human B cells, respectively [70] . Mutations within one allele of CD19 itself lead to ~2.4-fold reduced surface expression of CD19 [71] , while homozygous mutations in the exons encoding cytoplasmic residues of CD19 result in the generation of a truncated, dysfunctional CD19 molecule that is not recognized or is poorly recognized by standard anti-CD19 antibodies [72] . In almost all cases, dysregulated CD19 expression is associated with abnormalities of the immune system, as also suggested by the development of autoantibodies in mice carrying a human CD19 transgene leading to overexpression of CD19 [73] . Consistently, CD19 expression has also been reported to be dysregulated in peripheral B cells from autoimmune patients.
Overall, CD19 is expressed by almost all developmental and activation-dependent B-cell diff erentiation stages, except for certain PCs, and functions as an important regulator of specifi c B-cell activation by antigen ( Figure 1 ). CD19 expression coverage exceeds that shown by CD20 expression. Whether all types of B cells will be similarly targeted by therapeutic anti-CD19 antibodies requires fi rst experiences in patients treated with such antibodies.
Functions of CD19
On the surface of B cells, CD19 functions as a co-receptor of the BCR and contains two extracellular C2-type Ig-like domains. Th rough these domains, CD19 interacts with CD21 (CR2, C3d fragment receptor) and CD81, forming together with CD225 the BCR complex [74] .
Th e intracellular domain of CD19 is involved in intracellular signaling cascades, primarily but not exclusively regulating signals downstream of the BCR and CD22 [58] . Mice either lacking endogenous CD19 expression or overexpressing a human CD19 transgene under control of the endogenous promoter revealed that CD19 is essential for the normal function of the BCR, and in particular regulates the threshold for its activation. While CD19-defi cient mice show impaired B-cell responses, B cells from hCD19 transgenic mice were hyperresponsive [75, 76] and produce autoantibodies. CD19 is thus a regulator of BCR signaling threshold and is implicated in the control of peripheral tolerance [77] . Human CD19 defi ciency has no apparent impact on B-cell development but relates to the phenotype of CD19 -/mice, in that these patients suff er from antibody defi ciency [72] . CD19 has also been suggested to have a role in regulating cell proliferation, apparently independent of B-cell identity. CD19 transfection of multiple myeloma but also other cell lines led to reduced culture growth and tumor formation when injected in mice. Th is eff ect depended on the cytoplasmic part of CD19 [78] . Overall, the currently available data suggest that CD19 plays critical roles in B-cell and PC diff erentiation as well as in cell turnover.
CD19 expression by B cells in autoimmunity
Evaluation of anti-CD19 therapy as a therapeutic option requires careful consideration of CD19 expression levels by B cells from patients with autoimmune diseases.
CD19 expression levels of B-cell subsets in the blood
In the blood of patients with lupus, ANCA-associated vasculitis and systemic sclerosis, but also in healthy individuals, CD27 + (memory) B cells appear to express higher levels of CD19 than CD27 -(naïve) B cells [79] [80] [81] , perhaps corresponding to the distinct activation threshold of memory versus naïve B cells in response to antigen. Moreover, circulating CD27 high -expressing plasmablasts usually but not always show downregulated, however clearly detectable, expression of CD19 in autoimmune patients and healthy individuals [80] [81] [82] [83] [84] . Th e cell surface density of CD19 is lower than that of CD20 in normal B cells [85] . Th is diff erence probably has limited impli cations for the functionality and biological effi cacy of anti-CD19 versus anti-CD20 treatments, because specifi c modifi cations of the antibodies (engineering) prefer en tially defi ne target cell binding and clearing properties [86, 87] .
Disturbed expression of CD19 in SLE and other autoimmune diseases
In autoimmune patients, both reduced and enhanced CD19 expression by peripheral blood B cells has been described compared with healthy controls. Patients with systemic sclerosis displayed a ~20% increase of CD19 expression on peripheral blood B cells irrespective of whether naïve or memory B cells were analyzed [73, 81] . CD19 expression levels correlated with serum IgG and IgM concentrations but not with serum anti-nuclear antibody in these patients [73] . . During this process, CD19 expression starts at the stage of late pro-B cells and precedes that of CD20, starting in immature B cells. CD19 and CD20 expression is maintained during B-cell diff erentiation and activation in the periphery, while activation and diff erentiation into memory B cells may fi ne-tune expression levels. During activation of B cells in lymphoid organs -such as the spleen and tonsil, resulting in their diff erentiation into plasmablasts and fi nally plasma cells -CD20 expression is downregulated and subsequently lost. At the same time, CD19 expression is partially downregulated but not extinguished. Being released into circulation, only few plasmablasts express low amounts of CD20, while most have lost CD20 expression but express CD19. After successful immigration into deposits in the BM or the lamina propria (LP), all plasma cells lack CD20, while CD19 expression is maintained by one subset of tissue-resident plasma cells, while another subset acquires a CD19 -/CD20phenotype. Other surface molecules such as CD27, CD38 and CD138 do not qualify as therapeutic targets for global B-cell depletion approaches, as these are not continuously expressed throughout B-cell diff erentiation and their expression is shared with, for example, T lymphocytes and endothelial cells. In our analyses, average CD19 expression levels of memory and naive B cells from patients with SLE were comparable with those of healthy controls based on mean fl uorescence intensities, whereas plasmablasts showed a trend towards lower CD19 levels (Figure 2 ). However, CD19 levels detected on patients' memory cells and also naive B cells showed higher variability than those of healthy controls. Stratifi cation of the patient cohort according to high and low disease activity (Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)) or ascending expression levels of CD19 suggested an inverse correlation of CD19 expression levels with disease activity. Moreover, CD19 levels expressed by plasmablasts, memory cells and naive B cells strongly correlated with each other (P <0.0001). Overall, CD19 expression by plasmablasts was signifi cantly lower as compared with that of memory cells and naive B cells in both SLE patients and controls. Th is suggests that CD19 expression levels in B cells are regulated via diff erentiation-independent mechanisms as well as diff erentiation-dependent mechanisms. Other studies documented about 20% reduced CD19 expression levels by naïve and memory B cells from SLE patients [73, 81] . In this regard, our SLE cohort appears to comprise patients with either markedly higher or lower CD19 expression, while there were only few patients within the limited range of CD19 expression values of healthy individuals. Th ese data reproduce both upregulation and downregulation of CD19 by blood B cells from autoimmune patients, which may correspond to the previous observations of CD19 high B cells (as discussed below) or reduced CD19 expression [81] .
Overall, the reduction of CD19 expression by SLE B cells in at least some patients appears to be a reproducible phenomenon, independent of disease activity, the presence of anti-nuclear antibodies or use of the diff erent anti-CD19 antibodies applied to expression analyses [79, 80] . Interestingly, the diff erence of CD19 expression by B cells between healthy controls and SLE patients has not been found on a transcriptional level and was reversible after a 2-day, nonstimulating in vitro culture [80] .
Th ese data representing an apparent bidirectional dysregulation of CD19 expression by B cells from autoimmune patients are consistent with the fi ne-tuning of CD19 expression in vivo, which however may not be specifi cally linked to autoimmunity in general.
CD19 high B cells in SLE patients
Additional studies have characterized a population of CD19 high -expressing B cells in patients with SLE and ANCA-associated vasculitis, representing up to 10% of the B cells in most patients and up to 30% in individual cases [79, 88, 89] . CD19 high B cells showed markedly higher CD19 expression than B cells from healthy controls, while the remaining CD19 low B cells recapitulated the reduced CD19 expression [79] as also documented by other studies [73, 80, 81] . Detailed fl ow cytometric analyses of CD19 high B cells revealed increased forward-scatter signals compared with CD19 low B cells. CD19 high B cells mainly expressed CD27, and to a lesser degree IgD, and displayed increased expression of CD86, MHC II and CD95 [79, 89] consistent with recent activation of this putative memory B-cell subset in vivo. Consistently, CD19 high B cells displayed enhanced phosphorylation of signaling molecules downstream of the BCR complex, such as Syk and ERK, which distinguished them from CD19 low B cells [88] and could be generated in vitro from both BCR/CpG-activated naive or memory B cells [90] .
In SLE and other autoimmune and immune-defi cient patients, CD19 high B cells are characterized by low surface CD21 expression [70, 73, 79, 81, 89] . Th ese cells therefore resemble the phenotype of B cells that were reported as 'exhausted tissue-like memory B cells' in patients with HIV [91] or common variable immunodefi ciency [92] . In the latter, CD19 high B cells were not associated with autoimmune phenomena but with splenomegaly and cytopenia [92] . Th e presence of CD19 high /CD21 low B cells is hence not unique for patients with SLE and probably corresponds to distinct functional stages of activated B cells. In support of this hypothesis, such CD19 high B cells express reduced levels of CD62L (l-selectin), CXCR4 and CXCR5 [70, 89, 91] , which may exclude these cells from regular recirculation and germinal center participation, while enhanced expression of functional CXCR3 [88] might allow for their migration to sites of infl ammation in vivo.
Th e presence of CD19 high B cells did not correlate with disease activity in SLE or ANCA-associated vasculitis [79, 89] , but did correlate with neurological and renal disease manifestations [79, 88] , shorter clinical benefi t from rituximab treatment [88] as well as anti-Sm but not anti-nuclear antibody or anti-Ro/La titers [79] . Indeed, CD19 high B cells from anti-Sm-positive SLE patients yielded considerable amounts of Sm-specifi c antibodysecreting cells 6 days after in vitro activation culture, in contrast to CD19 low B cells [88] , suggesting that this subset might contain a substantial part of autoreactive B cells.
In summary, abnormalities in CD19 expression appear to be related to the activation status of B cells rather than specifi cally linked to autoimmunity (Table 3) . Th e combined data of CD19 expression in conjunction with changes of CD21, CD81, BCR and Btk suggest that CD19 expression is fi ne-tuned by BCR-mediated activation signals. Given the enhanced CD19 expression by some B cells under the condition of autoimmunity, these cells may constitute a key target. However, given that blood lymphocytes represent approximately 2% of total body lymphocytes [93, 94] , whether the data above are also representative for tissue-resident B cells in the spleen, lymph nodes, BM, gut-associated lymphoid tissues and infl amed sites remains open. Apparently all B-cell stages in the human blood and probably in the relevant tissues express CD19 and presumably could be targeted by an anti-CD19 antibody.
CD19 expression by plasma cells
Importantly, a substantial fraction of antibody-secreting PCs express CD19 in contrast to CD20, which is downregulated during plasmablast diff erentiation in association with their relocation from secondary lymphoid tissue to PC depots in the BM or lamina propria. Splenic and tonsillar plasmablasts appear as CD19 + CD20 +/intermediateexpressing cells [95] [96] [97] , while plasmablasts in the blood express low or no CD20 and diminished CD19 levels [80, 81, 83, 84, 96, 98] . One must emphasize that PCs in the BM consist of both CD20 -CD19 + and CD20 -CD19 -PC subsets in man [96, 99] and in the mouse [100] . Th e bimodal distribution of CD19 expression among PCs in the BM of both healthy and autoimmune individuals ( Figure 3 ) has important implications since CD19directed therapies could therefore target some, but not all, PCs.
Both PC diff erentiation and downregulation of CD19 are tightly interrelated with the loss of PAX5/BSAP expression [101, 102] , and consequently BSAP binding sites in the CD19 promoter are not occupied in PCs [59] . While many PC lines and multiple myeloma cells lack CD19 expression, fractions of normal mature PCs in the human BM but also in the mucosal lamina propria express CD19 [96, 99, [103] [104] [105] , including IgG-secreting cells in man [98] and Blimp-1 + PC in the mouse [100] .
Little is known about the nature of underlying immune reactions and/or the relationship between CD19 + and CD19 -PC in the BM or lamina propria, which makes it challenging to estimate the potential eff ects of CD19directed therapy on humoral (auto)immunity. In the mouse, the gradual loss of CD19 on PCs seems to be associated with advanced maturity; that is, higher expression of Blimp-1, lower expression of HLA-DR and B220, and eventually a longer lifespan [100] . Neither CD19 + nor CD19 -PCs from human BM expressed PAX5 mRNA, but they did express IRF4, PRDM1 and CD138 at comparable levels (n ≥4; HE Mei and T Dörner, un published data). Th is suggests additional factors regulating the expression of CD19 on PCs beyond transcriptional control by PAX5/BSAP.
Th ese data are consistent with the assumption that anti-CD19 therapy would probably target signifi cant fractions of PCs while not enhancing all PCs. More information is therefore required on the dynamics of and the relationship between CD19 + and CD19 -PCs in order to estimate the impact of anti-CD19 treatment.
Plasmablasts and certain plasma cells can be targeted by anti-CD19
CD19 + cells comprise virtually all antibody-secreting cells in the peripheral blood in both healthy individuals and patients with SLE as well as other autoimmune diseases [25, 83, 106] . Th ese comprise (at least) two major fractions: fi rst, recently generated antibody-secreting cells that undergo cell division, are capable of in vitro migration towards gradients of CXCL12 [25] , express high levels of HLA-DR and contain antigen-specifi c cells that pass the peripheral blood 1 week after a tetanus booster vaccination [83] . We termed these cells plasmablasts [7, 25, 36, 83] , whereas the remaining antibodysecret ing cells were defi ned as PCs that were unable to proliferate and migrate in vitro [25] , lack surface expression of the adhesion molecules β 7 -integrin and CD62L (l-selectin), express low levels of HLA-DR and do not contain antigen-specifi c cells after vaccination [25, 83] . When analyzed 1 week after tetanus vaccination, circulating HLA-DR low PCs phenotypically, functionally and transcriptionally showed a high degree of similarity with BM PCs [7, 25] , and probably refl ect outcompeted mature BM PCs [83] . Both subsets can be detected by fl ow cytometry after gating on CD19 + cells combined with an enlarged lymphocyte gate [25, [82] [83] [84] .
CD19 expression by plasmablasts in autoimmune diseases has rarely been analyzed. Sato and colleagues did not detect statistically signifi cant diff erences in the CD19 signals by fl ow cytometry when comparing plasmablasts (together with PCs using the CD27 high criterion for detection) among healthy individuals and patients with SLE or systemic sclerosis [81] -while another study showed lower CD19 expression by SLE CD27 high plasmablasts as compared with those from healthy controls [80] , which is consistent with our data (Figure 2) . As illustrated in a representative SLE patient, approximately 80% of the peripheral blood CD138 + plasmablasts/PCs express CD19 [84] , indicating that a minority of circulating PCs lacks expression of this marker. Frequencies and numbers of CD19-expressing plasmablasts/PCs are drastically increased in patients with SLE [54, 82, 84, 107] and refl ect up to 50% of all circulating CD19 + B cells [84] while containing dsDNA-specifi c cells [54] . Th e cell frequency and number correlated with disease activity and autoantibody production [82, 84, 106] , and this correlation was even more pronounced when HLA-DR high plasmablasts were analyzed separately [54] . Th e presence of these plasmablasts therefore refl ects acute, presumably pathogenic B-cell activation in patients with SLE. Elevation of peripheral blood plasmablast levels has also been recently demonstrated for Takayasu's arteriitis patients [108] , but not in patients with primary Sjögren's syndrome [109] , autoimmune thrombo cytopenia [110] , systemic sclerosis [81] and RA [19] . Further analyses focusing on CD19 + B cells in the BM demonstrated an imbalance of HLA-DR high plasmablasts versus HLA-DR low PC subsets -that is, relative expansion of plasmablasts in SLE patients' BM -indicating that not only the periphery but also the major deposit sites of PC are disturbed in SLE [54] .
Th e prominent presence of presumably pathogenic plasmablasts in SLE patients' blood and BM [3] provide a further rationale for anti-CD19 therapy since CD19 + CD20 -/low plasmablasts are refractory to B-cell depletion with rituximab in RA, SLE and other autoimmune syndromes [19, 21, [111] [112] [113] [114] . In this context, we found that rituximab-resistant plasmablasts carry a mucosal phenotype in patients with RA and show multiple traits of their recent generation, such as cell proliferation and spontaneous in vitro migration. Th is fi nding points towards a self-suffi cient, rituximab-resistant mucosal B-cell subset in man [19] that is chronically activated and gives rise to plasmablasts in circulation. In SLE patients, higher levels of plasmablasts after B-cell depletion have been reported to be associated with poorer clinical response [112] . Anti-CD19 therapy might constitute a possibility to overcome this limitation of rituximab by directly targeting these plasmablasts and certain CD19 + PCs. Th ere is thus a possibility that especially autoantibody-positive patients could benefi t from anti-CD19 therapy, but this needs to be demonstrated.
Overall, a better understanding of the homeostasis and diff erentiation of diff erent mature PC subsets in healthy subjects and autoimmune patients not only related to the expression of CD19 but also to their distribution and characteristics in certain organs and organ systems is required to fully explore the potential benefi ts and potential side eff ects of, and suitable molecular targets for PC-directed therapies.
Anti-CD19 treatment approaches and eff ects on antibody production
Autoreactive clones of long-lived PCs have been considered an obstacle for existing therapies in autoimmunity [3] , while anti-CD19 therapies have been initially developed to delete malignant B-cell clones using both native and modifi ed anti-CD19 antibodies with or without conjugated toxins as well as bispecifi c antibodies targeting, for example, CD19 and CD3 or transgenic T cells carrying a T-cell receptor recognizing CD19. Although approaches in oncology diff er in their rationales compared with autoimmunity, the existing data for anti-CD19 antibodies in treating malignant diseases represent a valuable mechanism of action and a safety data pool.
Native naked and conjugated anti-CD19 antibodies
Initial studies in non-Hodgkin's lymphoma patients [115, 116] using CLB-CD19 with or without IL-2 demonstrated binding of anti-CD19 antibody to B cells in vivo and led to partial reduction of blood B cells, but did not consistently change total antibody levels during treatment (up to 12 weeks) and in the follow-up period.
Various anti-CD19 immunotoxins are under development for malignant diseases -for example, bound to auristatin [117] , saporin [118] or ricin [119] -but have not so far entered studies in autoimmunity.
In a mouse model of anti-CD19 therapy using hCD19 transgenic mice [120] and anti-human CD19 antibodies (HB12a, HB12b and FMC63), depletion of >90% of B cells in the BM, blood, spleen and lymph nodes was observed, while peritoneal cavity B cells were reduced by only twothirds. Notably, pro-B cells in the BM were not depleted in this system. Blood B cells remained depleted for about 12 weeks and only partially repopulated until 30 weeks after treatment. In this model, levels of total serum antibody concentrations were reduced by 95% for IgM, by 10 to 20% for IgG and by about 40% for IgA compared with baseline values. Specifi c IgM and IgG 1 responses to T-independent antigens and primary and secondary responses to T-dependent antigens were virtually abrogated in mice treated with anti-CD19. Reduction of specifi c serum IgM and IgG 1 concentrations also occurred in previously immunized mice treated with anti-CD19 [120] , most probably refl ecting that antibodysecreting cells were successfully targeted in this model. Autoantibody production analyzed in this mouse model was critically dependent on the overexpression of CD19 [121, 122] , and CD19 expression was reduced over at least 10 weeks after anti-CD19 therapy. While animals treated with control antibody developed increasing levels of anti-dsDNA, anti-ssDNA and anti-histone IgM and IgG antibodies, anti-CD19-treated mice showed reductions of IgM autoantibodies within 2 weeks. IgG autoantibodies were also reduced in a delayed manner at the latest by week 10 after treatment [120] . Th ese Ig-classspecifi c responses of serum antibody levels to anti-CD19 treatment indicate diff erential dynamics of IgM + and IgG + PC subsets and indicate that some but perhaps not all autoreactive PCs express CD19 in this model. However, additional studies are required in control mice and in models of SLE that are independent of genetic modification of CD19 expression.
Engineered anti-CD19 antibodies
Modifi cations of the amino acid sequence and the glycosylation of native anti-CD19 antibodies [86, 87] , as well as engineering of bispecifi c antibodies co-targeting other antigens (for example, CD3 [123] ) to enhance target cell binding clearing properties, have generated interest in anti-CD19 immunotherapy.
In this context, the bispecifi c CD19×CD3 antibody (Blinatumomab, MT103, MEDI-538, bispecifi c T-cell engager (BiTE)) that has been designed to recruit and activate T cells in the vicinity of CD19 + tumor cells in non-Hodgkin's lymphoma patients resulted in substantial and effi cacious depletion of blood B cells (residual numbers <10 cells/μl) for up to 2 months and obviously cleared malignant B cells in the BM, spleen and liver. More than 85% of the study participants showed no signifi cant decline of serum Ig levels, refl ecting that most patients retained an intact PC compartment during therapy.
Th e application of XmAb5574 (MOR208) in Cyno molgus monkeys did not reduce serum IgG, IgA and IgM levels over a 3-month period [124] , indicating that the PC compartment remained intact either due to resistance of PCs or incomplete depletion of B cells in this model. Indeed, only 80 to 90% of CD20 + B cells in peripheral blood and 40 to 60% within the BM, spleen and lymph nodes were depleted 1 month after anti-CD19 treatment [124] . A clinical phase I trial with XmAb5574 in chronic lymphocytic leukemia patients is currently ongoing (Trial #NCT01161511). A further anti-CD19 antibody is MEDI-551, which is able to deplete B cells in suspensions of human peripheral blood mononuclear cells as well as blood and splenic B cells in hCD19/hCD20 double transgenic mice [86] . Data that might allow an evaluation of targeting PC in humans by this antibody are not yet available, but clinical trials have been initiated. Th e anti-CD19 antibody MDX-1342 was under investigation in RA patients in combination with methotrexate [125] but was discontinued in April 2010. Further anti-CD19 approaches such as derivates of the anti-human CD19 clone HD37 are being developed [126] .
Multiple anti-CD19 antibodies are being and have been developed for therapeutic use, so far with very inconsistent experiences in preclinical models or pilot trials with regard to both the effi cacy and duration of B-cell and PC depletion.
Anti-CD19 chimeric antigen receptor-expressing T cells
A diff erent way of CD19 targeting employs transplants of autologous T lymphocytes that are isolated from the patients' blood, stimulated in vitro with, for example, anti-CD3 and IL-2, and transduced with a vector conferring expression of a chimeric antigen receptor (CAR) that is directed against CD19. Upon incubation with CD19 + cells, CAR-bearing T cells produce IFNγ and IL-2 [127, 128] and lead to sustained depletion of B cells, including tumor cells in human blood (at least for 40 weeks) and in BM (at least for 36 weeks) [127] . Notably, serum Ig levels gradually dropped during this therapy with reductions of approximately 40 to 50% for IgG within 14 weeks, 85% (within 14 weeks) and 75% (until week 36) for IgA and IgM, respectively. In a subsequent study of eight non-Hodgkin's lymphoma patients, four individuals experienced profound B-cell depletion with hypogammaglobulinemia requiring Ig substitution [129] -similar to that described for treatment of chronic lymphocytic leukemia patients using CD19 CAR-expressing T cells [130] . Depletion failed in the other four patients, as has also been reported by an independent study [131] , and was probably due to proper ties of the malignant B cells or result from variations of CD19 chimeric antigen receptor T-cell generation.
Th e available data on B-cell and PC targeting by anti-CD19-directed approaches in oncologic diseases do not allow fi rm conclusions as to what extent PC depletion occurs in autoimmunity and may diff er between certain agents and techniques. Ongoing clinical studies will provide more detailed information on the effi cacy and especially safety of anti-CD19 approaches, which will also permit a unique opportunity to compare those with anti-CD20 experiences and at the same time better defi ne potential treatment options for autoimmunity.
Potential risks and benefi ts of anti-CD19 therapy in autoimmunity
Humoral immunity and the potential risks for infections Apparently, targeting both B cells and PCs raises safety concerns with regard to suffi cient control of environmental pathogens and infections by protective Ig generated as a fi rst-line defense as well as during B-cell memory responses. CD19 targeting can be assumed to enlarge the window of cell depletion compared with anti-CD20 therapy, with an additional impact on pro-B cells and PCs. As the maintenance of protective and autoreactive antibody titers and the contributions of diff erent subsets of CD19 + versus CD19 -PCs and CD19 + plasmablasts are incompletely understood, one may only speculate about the impact of anti-CD19 on immune protection. Successful targeting of CD19 + PCs in patients with SLE is expected to at least substantially reduce autoantibody titers produced by plasmablasts and certain PCs. However, severe reductions of Ig levels can be managed by intravenous Ig infusions [129] . We believe one cannot exclude the possibility that patients might experience loss of or impairment of suffi cient antibody production under anti-CD19 therapy, as observed in patients with common variable immunodefi ciency who often show reduced numbers of PCs in the BM [132] and usually fail to mount suffi cient vaccination responses [133] . Th e failure to suffi ciently respond to vaccinations of most patients treated with anti-CD20 will probably also aff ect patients treated with anti-CD19 therapy. During rituximab treatment, both primary and secondary serological antibody responses are substantially impaired [134] [135] [136] [137] [138] , while pre-existing antibody titers were largely maintained. Th e estimated time period of B-cell absence after anti-CD19-mediated B-cell depletion is currently unknown, while B-cell depletion with rituximab lasts usually 6 months or longer. Given the broader coverage of anti-CD19 that includes pro-B cells, it is possible that peripheral B-cell repopulation after anti-CD19 therapy diff ers from that after anti-CD20 therapy.
A situation of antibody defi ciency has been described in SLE patients after ASCT with prior immunoablation using high-dose cyclophosphamide and rabbit antithymocyte globulin, which often leads to improvement of the disease, perhaps remission, but also caused loss of protective serum antibody titers directed to both protein and viral antigens (anti-tetanus, anti-measles, anti-diphtheria, anti-rubella) [5] . Th e risk of opportunistic infections therefore requires careful monitoring and potentially might represent a limitation. Given that diminishing autoimmune PCs provides substantial benefi t for the patients, including long-term remission, the possibility of intravenous Ig substitution may allow balancing the risk of hypoimmunoglobulinemia and infections.
Experiences with this therapy in tumor patients [123, 127, 129, 131] might in part be instructive for potential risks of anti-CD19 therapy in autoimmunity but can only be extrapolated with caution because of the diff erent underlying disease and pre-existing and comedications. Further potential side eff ects of anti-CD19 therapy probably overlap with various adverse events reported after B-cell depletion with rituximab, such as the occurrence of infections [139, 140] , suppression of specifi c B-cell responses [134] [135] [136] and risk to develop progressive multifocal leukoencephalopathy [141] . Th ese aspects are of particular importance since B-cell depletion by anti-CD19 strategies appears to be broad and long-lasting [129] while B cells and antibody is required to suppress John Cunningham virus (see [141] ). Overall, the safety profi le of anti-CD19 therapy in autoimmunity will be of central importance but requires further data.
CD19 ligation as an additional mechanism beyond depletion
Animal model data for anti-CD19 therapy documented effi cient reductions but sometimes not complete depletion of B cells [120, 124] . In such cases, B cells labeled by anti-CD19 would remain in vivo, with as yet unclear consequences for the modulation of BCR signaling [75, 77, 121] . In vitro, anti-CD19 (HD37) lowers the threshold for anti-BCR (IgM)-induced human B-cell activation under certain conditions [142] , which could confer enhanced B-cell activation and even exacerbation of autoimmunity, while other reports using diff erent protocols reported an inhibition of BCR signaling by anti-CD19 antibody. Th e above notions remain a theoretical possibility since overactivation of B cells during anti-CD19 treatment has not so far been reported.
Regulatory B cells
B-cell depletion also aff ects B cells with immunosuppressive potential, which might explain some rare cases of autoimmunity that were reported during rituximab therapy [143] [144] [145] [146] . In this regard, several studies in mice indicate an important role of B cells producing IL-10 in controlling autoimmunity [147] . In vitro generated IL-10-producing B cells express CD19 [148, 149] and were therefore subject to CD19-directed depletion. Th e phenotype and the importance of human bona fi de IL-10-secreting B cells in vivo remains unknown, however, and there is no clear evidence for impaired control of immune responses after either anti-CD19 or anti-CD20 therapy in humans.
Th e estimated immunological side eff ects of envisaged B-cell depletion using CD19-directed approaches mostly resemble the experiences from rituximab treatment. While additional putative depletion of pro-B cells leading to prolonged peripheral reconstitution and reductions of major PC subsets might lead to an enhanced risk for infections, CD19 therapy has the promise to improve effi cacy compared with the more restricted B-cell targeting by anti-CD20 antibodies.
MEDI 545 is in clinical development by Medimmune Inc.
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